l stage antibody is adecatumumab, also known as MT201, a traditional
human monoclonal antibody that targets EpCAM-expressing solid tumors.
Micromet is developing adecatumumab in collaboration with Merck Serono in a
phase 1b clinical trial evaluating adecatumumab in combination with
docetaxel for the treatment of patients with metastatic breast cancer.
Micromet licensed a fourth clinical stage antibody, MT 293, to TRACON
Pharmaceuticals, Inc. MT 293 is being developed in a phase 1 clinical trial
for the treatment of patients with cancer. The Company's preclinical
programs include MT 203 being developed in collaboration with Nycomed. MT
203 is a traditional human antibody neutralizing the activity of
granulocyte/macrophage colony stimulating factor (GM-CSF), which has
potential applications in the treatment of inflammatory and autoimmune
diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.
Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP,
respectively, are in different stages of preclinical development.
This press release contains certain forward-looking statements that
involve risks and uncertainties that could cause actual results to be
materially different from historical results or from any future results
expressed or implied by such forward-looking statements. These
forward-looking statements include statements regarding the efficacy,
safety and intended utilization of our product candidates, the development
of our BiTE antibody technology, the conduct, timing and results of future
clinical trials, expectations of the future expansion of our product
pipeline and collaborations, and our plans regarding future presentations
of clinical data. You are urged to consider statements that include the
words "ongoing," "may," "will," "believes," "potential," "expects,"
"plans," "anticipates," "intends," "suggests," "could," or "consider" or
the negative of those words or other similar words tPage: 1 2 3 4 5 6 7 8 9 Related biology technology :1
. Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results2
. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule3
. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer4
. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results5
. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results6
. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors7
. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference8
. EntreMed Reports Third Quarter 2008 Financial Results9
. CV Therapeutics Reports 2008 Third Quarter Financial Results10
. Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase11
. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results